Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa

Tania M Gonzalez Santiago, Andrey Zavialov, Janna Saarela, Mikko Seppanen, Ann M. Reed, Roshini S. Abraham, Lawrence E. Gibson

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

IMPORTANCE: Mutations in the CERC1 gene associated with deficiency in the ADA2 protein (DADA2) have been implicated in the pathogenesis of cutaneous polyarteritis nodosa (cPAN) and early-onset vasculopathy. DADA2 is not only limited to cPAN and vasculopathy but also includes immunodeficiency that affects several cellular compartments, including B cells; however, some patients appear to have a more indolent, skin-limited disease. OBSERVATIONS: In this report, we describe 2 white siblings (female and male) with a history of cPAN with DADA2 as a result of novel compound heterozygous mutations inherited in trans in the CECR1 gene (c.37-39del [p.K13del] and c.1159C>A [p.N328K]). The onset of disease was earlier in the female sibling than the male sibling although both were diagnosed as having cPAN in early childhood. The disease is associated with a more significant immunodeficiency and other systemic symptoms in the female than the male sibling. CONCLUSIONS AND RELEVANCE: These findings suggest a genetic cause of cPAN in some patients. Therefore, DADA2 should be considered in patients with cPAN, specifically in those whose conditions are diagnosed at an early age, regardless of their ethnicity, presence or absence of systemic symptoms, or a family history of the disease.

Original languageEnglish (US)
Pages (from-to)1230-1234
Number of pages5
JournalJAMA Dermatology
Volume151
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Polyarteritis Nodosa
Skin
Siblings
Proteins
Mutation
Skin Diseases
Genes
B-Lymphocytes

ASJC Scopus subject areas

  • Dermatology

Cite this

Santiago, T. M. G., Zavialov, A., Saarela, J., Seppanen, M., Reed, A. M., Abraham, R. S., & Gibson, L. E. (2015). Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatology, 151(11), 1230-1234. https://doi.org/10.1001/jamadermatol.2015.1635

Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. / Santiago, Tania M Gonzalez; Zavialov, Andrey; Saarela, Janna; Seppanen, Mikko; Reed, Ann M.; Abraham, Roshini S.; Gibson, Lawrence E.

In: JAMA Dermatology, Vol. 151, No. 11, 01.11.2015, p. 1230-1234.

Research output: Contribution to journalArticle

Santiago, TMG, Zavialov, A, Saarela, J, Seppanen, M, Reed, AM, Abraham, RS & Gibson, LE 2015, 'Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa', JAMA Dermatology, vol. 151, no. 11, pp. 1230-1234. https://doi.org/10.1001/jamadermatol.2015.1635
Santiago TMG, Zavialov A, Saarela J, Seppanen M, Reed AM, Abraham RS et al. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatology. 2015 Nov 1;151(11):1230-1234. https://doi.org/10.1001/jamadermatol.2015.1635
Santiago, Tania M Gonzalez ; Zavialov, Andrey ; Saarela, Janna ; Seppanen, Mikko ; Reed, Ann M. ; Abraham, Roshini S. ; Gibson, Lawrence E. / Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. In: JAMA Dermatology. 2015 ; Vol. 151, No. 11. pp. 1230-1234.
@article{672ba54f377d4b60a92b349b1745f3ba,
title = "Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa",
abstract = "IMPORTANCE: Mutations in the CERC1 gene associated with deficiency in the ADA2 protein (DADA2) have been implicated in the pathogenesis of cutaneous polyarteritis nodosa (cPAN) and early-onset vasculopathy. DADA2 is not only limited to cPAN and vasculopathy but also includes immunodeficiency that affects several cellular compartments, including B cells; however, some patients appear to have a more indolent, skin-limited disease. OBSERVATIONS: In this report, we describe 2 white siblings (female and male) with a history of cPAN with DADA2 as a result of novel compound heterozygous mutations inherited in trans in the CECR1 gene (c.37-39del [p.K13del] and c.1159C>A [p.N328K]). The onset of disease was earlier in the female sibling than the male sibling although both were diagnosed as having cPAN in early childhood. The disease is associated with a more significant immunodeficiency and other systemic symptoms in the female than the male sibling. CONCLUSIONS AND RELEVANCE: These findings suggest a genetic cause of cPAN in some patients. Therefore, DADA2 should be considered in patients with cPAN, specifically in those whose conditions are diagnosed at an early age, regardless of their ethnicity, presence or absence of systemic symptoms, or a family history of the disease.",
author = "Santiago, {Tania M Gonzalez} and Andrey Zavialov and Janna Saarela and Mikko Seppanen and Reed, {Ann M.} and Abraham, {Roshini S.} and Gibson, {Lawrence E.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1001/jamadermatol.2015.1635",
language = "English (US)",
volume = "151",
pages = "1230--1234",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa

AU - Santiago, Tania M Gonzalez

AU - Zavialov, Andrey

AU - Saarela, Janna

AU - Seppanen, Mikko

AU - Reed, Ann M.

AU - Abraham, Roshini S.

AU - Gibson, Lawrence E.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - IMPORTANCE: Mutations in the CERC1 gene associated with deficiency in the ADA2 protein (DADA2) have been implicated in the pathogenesis of cutaneous polyarteritis nodosa (cPAN) and early-onset vasculopathy. DADA2 is not only limited to cPAN and vasculopathy but also includes immunodeficiency that affects several cellular compartments, including B cells; however, some patients appear to have a more indolent, skin-limited disease. OBSERVATIONS: In this report, we describe 2 white siblings (female and male) with a history of cPAN with DADA2 as a result of novel compound heterozygous mutations inherited in trans in the CECR1 gene (c.37-39del [p.K13del] and c.1159C>A [p.N328K]). The onset of disease was earlier in the female sibling than the male sibling although both were diagnosed as having cPAN in early childhood. The disease is associated with a more significant immunodeficiency and other systemic symptoms in the female than the male sibling. CONCLUSIONS AND RELEVANCE: These findings suggest a genetic cause of cPAN in some patients. Therefore, DADA2 should be considered in patients with cPAN, specifically in those whose conditions are diagnosed at an early age, regardless of their ethnicity, presence or absence of systemic symptoms, or a family history of the disease.

AB - IMPORTANCE: Mutations in the CERC1 gene associated with deficiency in the ADA2 protein (DADA2) have been implicated in the pathogenesis of cutaneous polyarteritis nodosa (cPAN) and early-onset vasculopathy. DADA2 is not only limited to cPAN and vasculopathy but also includes immunodeficiency that affects several cellular compartments, including B cells; however, some patients appear to have a more indolent, skin-limited disease. OBSERVATIONS: In this report, we describe 2 white siblings (female and male) with a history of cPAN with DADA2 as a result of novel compound heterozygous mutations inherited in trans in the CECR1 gene (c.37-39del [p.K13del] and c.1159C>A [p.N328K]). The onset of disease was earlier in the female sibling than the male sibling although both were diagnosed as having cPAN in early childhood. The disease is associated with a more significant immunodeficiency and other systemic symptoms in the female than the male sibling. CONCLUSIONS AND RELEVANCE: These findings suggest a genetic cause of cPAN in some patients. Therefore, DADA2 should be considered in patients with cPAN, specifically in those whose conditions are diagnosed at an early age, regardless of their ethnicity, presence or absence of systemic symptoms, or a family history of the disease.

UR - http://www.scopus.com/inward/record.url?scp=84946865962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946865962&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2015.1635

DO - 10.1001/jamadermatol.2015.1635

M3 - Article

C2 - 26131734

AN - SCOPUS:84946865962

VL - 151

SP - 1230

EP - 1234

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 11

ER -